- Home
- CNTB vs ALDX Comparison
CNTB vs ALDX Comparison
Compare CNTB & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | ALDX |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.7M | 124.9M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CNTB | ALDX |
|---|---|---|
| Price | $2.33 | $1.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $8.67 | $5.50 |
| AVG Volume (30 Days) | 328.4K | ★ 885.4K |
| Earning Date | 08-13-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $64,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.23 | $1.07 |
| 52 Week High | $3.82 | $6.18 |
Technical Indicators
Market Signals| Indicator | CNTB | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 42.31 |
| Support Level | $2.30 | $1.47 |
| Resistance Level | $2.69 | $1.88 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 57.30 | 44.74 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.